Protection of endogenous enkephalin degradation from peptidases in human serum by actinonin.
This paper describes a new method for detecting the endogenous enkephalin level in human serum without interference from serum peptidases and contaminating proteins. The method consists of a combination of addition of a peptidase inhibitor, actinonin to serum and dialysis. The activity of enkephalin degrading enzymes was completely abolished by actinonin. Furthermore, contaminating proteins which interfered with RIA assay of enkephalins were removed by the dialysis process. This combination process enabled precise detection of the concentration of enkephalin-like substances in human serum. The mean normal serum level of leucine-enkephalin assayed by this method in 12 healthy volunteers was 93.4 pg/ml.
Nakajima
S
S
Department of Anesthesiology, School of Medicine, Juntendo University, Tokyo, Japan.
Kaya
K
K
Hazato
T
T
D000328:Adult; D000626:Aminopeptidases / Q000037:antagonists & inhibitors; D002851:Chromatography, High Pressure Liquid; D003956:Dialysis; D004743:Enkephalin, Leucine / Q000097:blood*; D005260:Female; D006801:Humans; D006877:Hydroxamic Acids / Q000494:pharmacology; D008297:Male; D008875:Middle Aged; D011863:Radioimmunoassay
D006877:Hydroxamic Acids; D004743:Enkephalin, Leucine; D000626:Aminopeptidases; C025579:enkephalin degrading enzyme; C010531:actinonin